Roche Holding AG Company Profile (OTCMKTS:RHHBY)

Analyst Ratings

Consensus Ratings for Roche Holding AG (OTCMKTS:RHHBY) (?)
Ratings Breakdown: 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $177.50

Analysts' Ratings History for Roche Holding AG (OTCMKTS:RHHBY)
Show:
DateFirmActionRatingPrice TargetActions
5/13/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016Piper Jaffray Cos.Initiated CoverageOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/20/2015Cowen and CompanyDowngradeOutperform -> Market Perform$42.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2015Credit Suisse Group AGReiterated RatingOutperform$320.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015Baader BankUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2015HSBCInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2015Erste GroupInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/13/2015Liberum CapitalDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2015Bryan, Garnier & CoUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/25/2014BNP ParibasInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2014Kepler Capital MarketsDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Roche Holding AG (OTCMKTS:RHHBY)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Roche Holding AG (OTCMKTS:RHHBY)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Roche Holding AG (OTCMKTS:RHHBY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Roche Holding AG (OTCMKTS:RHHBY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Roche Holding AG (OTCMKTS:RHHBY)
DateHeadline
07/22/16 05:01 PMDissecting Roche’s Performance across Its Segments -
07/22/16 05:01 PMReasons behind Roche’s Better-than-Expected 2Q16 Performance -
07/21/16 06:27 PMAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin - Wall Street Journal
07/21/16 06:27 PMRoche Sales Rise on Cancer Drugs - Wall Street Journal
07/21/16 05:35 AM[$$] Roche says UK faces losing lead in medical research after Brexit - [at Financial Times] - Roche, the Swiss pharmaceutical company, has warned that the UK risks losing its lead in medical research after leaving the EU. The Swiss group called for Britain to move quickly to replace European regulations ...
07/21/16 03:38 AMRoche CEO Confident Business Will Succeed Despite Turmoil -
07/19/16 07:06 AMAre Analysts Bearish Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) After Last Week? - Consumer Eagle
07/18/16 05:42 PMRoche's Gazyva Fails in Phase III B-cell Lymphoma Study -
07/18/16 11:37 AMRoche : provides update on phase III study of Gazyva/Gazyvaro in people with previously untreated diffuse large B-cell lymphoma
07/18/16 03:45 AMRoche Blood Cancer Medicine Fails to Show Major Improvement -
07/17/16 05:31 PMHow Much Upward Potential Does Roche Really Have? - Market Realist
07/15/16 07:02 PMHow Much Upward Potential Does Roche Really Have? -
07/15/16 11:52 AMCoaguChek® PT/ INR devices for use at the point of care and for patient self-testing remain a safe and effective option for patients on anticoagulation therapy - [PR Newswire] - INDIANAPOLIS, July 15, 2016 /PRNewswire/ -- Point-of-care and patient self-testing (PST) are growing standards of care for patients requiring regular PT/INR tests for warfarin therapy. These convenient ...
07/14/16 06:24 PMCelgene's R&D, Part 1: Background And The Juno Story - Seeking Alpha
07/14/16 06:24 PMNovartis' Enbrel Biosimilar Gets FDA Panel Recommendation - Nasdaq
07/14/16 06:24 PMCravath, Swaine & Moore Names Faiza Saeed as Presiding Partner - Wall Street Journal
07/14/16 09:44 AMCelgene's R&D, Part 1: Background, And The Juno Story
07/14/16 09:44 AMAmgen and Daiichi Sankyo Team Up for Biosimilars in Japan
07/13/16 09:01 AMShire's (SHPG) Dry Eye Disease Drug Xiidra Gets FDA Nod - Yahoo Finance
07/13/16 09:01 AMSucampo to Stop Developing Cobiprostone for Oral Mucositis - Yahoo Finance
07/13/16 08:25 AMPfizer (PFE) Gets FDA Nod for Label Expansion of Prevnar 13 -
07/11/16 12:24 PMRoche Holdings Definitely Not a Lumbering Giant -
07/11/16 10:47 AMNext Weeks Broker Price Targets For Roche Holding Ltd. (RHHBY) - Fiscal Standard
07/09/16 06:03 AM7:03 am Roche Hldg confirms FDA approval for performing the cobas HPV Test from cervical specimens collected in BD SurePath Preservative Fluid using the BD SurePath vial -
07/08/16 06:07 PMBroker Outlook For Roche Holding Ltd. (RHHBY) - Fiscal Standard
07/08/16 05:23 PMRoche Asthma Drug Xolair Gets FDA Nod for Label Expansion -
07/08/16 03:52 PMHere’s Why HPV-Related Cancers Are Rising Among American Men -
07/07/16 08:29 AMRoche Said To Mull BioMarin Buyout, Driving Up Stock -
07/06/16 09:20 AMRoche Holding AG :RHHBY-US: Earnings Analysis: For the six months ended December 31, 2015 : July 6, 2016 -
07/04/16 05:17 PMWhy Pfizer Inc, Amgen, Inc. are Just as Fitting for Medivation Inc as Sanofi SA - Bidness ETC
07/04/16 05:17 PMHow Many Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)'s Analysts Are Bullish? - Engelwood Daily
07/04/16 11:36 AMBIOCAD: Sri Lankan Court Dismisses F. Hoffmann-La Roche’s Lawsuit To Ban the Distribution Of Trastuzumab And Bevacizumab produced by BIOCAD - [Business Wire] - SAINT-PETERSBURG, Russia--(BUSINESSWIRE)-- Due to claims by Swiss drug-maker F. Hoffmann-La Roche, Ltd. in an attempt to cease the distribution of the Russian-made anti-tumor biosimilar products, as well as seeking to revoke BIOCAD’s product market authorization in Sri Lanka, cancer patients in this South-East country haven’t received the essential anti-cancer drugs trastuzumab and bevacizumab. After a series of hearings, in June 2016 the Court of Appeals of Sri Lanka finally dismissed the claims from the Swiss originator and terminated interim in relief. In late March this year F. Hoffmann-La Roche Ltd. filed a lawsuit against a local distributor of BIOCAD in Sri Lanka, asking to ban the distribution of trastuzumab and bevacizumab manufactured in the Russian Federation by a leading Russian biotechnology company, JCS BIOCAD.
06/29/16 02:20 PMRoche's Multiple Sclerosis Drug Under Review by FDA, EMA -
06/28/16 06:02 PMRoche Holding Ltd. (RHHBY) Updated Price Targets - FTSE News
06/28/16 12:49 PM[video]Instead of Panicking on Brexit, Buy These Stocks -
06/27/16 10:16 AMWere Analysts Bearish Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) This Week? - Press Telegraph
06/23/16 06:43 PMNew Broker Ratings For Roche Holding Ltd. (RHHBY) - FTSE News
06/23/16 07:32 AMEpizyme Teams Up with Roche's Genentech for Tazemetostat -
06/22/16 01:31 PMRoche CEO 'sleeps better' as risk to drugmaker's growth recedes -
06/20/16 07:41 AMRoche : launches the new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing
06/16/16 06:21 PMRoche : Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma
06/16/16 07:15 AMMerck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer -
06/15/16 06:01 PMRoche Holding Ltd. Ready to Enter IL-6 Antagonist Antibody Technology - Business Finance News
06/13/16 09:57 AMEleven Biotherapeutics Inc (EBIO) Soars on Roche Holding Ltd. (ADR) Deal - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Eleven Biotherapeutics stock soared on Monday following news of its deal with Roche concerning its Interleukin-6 technology. The post Eleven Biotherapeutics Inc (EBIO) Soars on Roche Holding Ltd. (ADR) Deal appeared first on InvestorPlace.
06/08/16 09:08 AMRoche : receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
06/06/16 06:03 PMRoche : Genentech's Cancer Immunotherapy Tecentriq (Atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer
06/06/16 06:03 PMCombination Treatment Could Heighten Pricing Pressures On Johnson & Johnson (NYSE:JNJ)?
06/06/16 03:49 PMRoche Presents Encouraging Data on Actemra and Tecentriq -
06/06/16 11:53 AMPhase III Study Shows Genentech’s Actemra® (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA) - [Business Wire] - Genentech, a member of the Roche Group , today announced positive results from the Phase III study known as GiACTA, which evaluated Actemra® in people with giant cell arteritis .
06/06/16 09:49 AMRoche : cancer immunotherapy Tecentriq (atezolizumab) shrank tumours in people with previously untreated advanced bladder cancer

Social

About Roche Holding AG

Roche Holding AG logoRoche Holding AG is a research-based healthcare company. The Company develops, manufactures and delivers medicines, and diagnostic instruments and tests. Its operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. Its Pharmaceuticals division consists of two business segments: Roche Pharmaceuticals and Chugai. Its Diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. It develops medicines for the disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its product portfolio consists of Pharmaceuticals, Solutions for Diagnostics and Products for Researchers. Its Pharmaceutical products include ACTEMRA and CellCept. Its Solutions for Diagnostics products include Accu-Chek Active System and Accu-Chek Aviva Nano System. The Company's Products for Researchers include Cedex HiRes and Genome Sequencer FLX System.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: RHHBY
  • CUSIP:
Key Metrics:
  • Previous Close: $31.69
  • 50 Day Moving Average: $32.24
  • 200 Day Moving Average: $31.90
  • P/E Ratio: 24.20
  • P/E Growth: 2.06
  • Market Cap: $215.99B
  • Beta: 0.68
  • Current Year EPS Consensus Estimate: $1.87 EPS
  • Next Year EPS Consensus Estimate: $2.44 EPS
Additional Links:
Roche Holding AG (OTCMKTS:RHHBY) Chart for Saturday, July, 23, 2016